Article Text

Download PDFPDF
The generic-patent medicine conflict flares up again in The Netherlands
  1. D O E Gebhardt
  1. Correspondence to:
 D O E Gebhardt
 Anna van Burenlaan 1, 2341 VE Oegstgeest, The Netherlands; doe.gebhardt{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Recently I reported in this journal1 how it became necessary for a judge to settle a dispute between the pharmaceutical industry and certain Dutch pharmacists. It considered the question of whether a pharmacist is permitted, without prior consultation, to give a patient a (cheaper) generic drug instead of the patent drug mentioned on the prescription.

Another dispute has now arisen after the pharmaceutical industry discovered that healthcare insurers were paying general practitioners (GPs) a bonus if they prescribed generic drugs, such as simvastatin (which reduces cholesterol content) or omeprazol (which reduces the …

View Full Text